ArticleThe oncologist2025
Intravenous haloperidol or chlorpromazine-which is more effective to improve agitation and communication in agitated delirium at the end of life?
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundDelirium frequently occurs in terminally ill patients with cancer. The purpose of this study was to determine whether intravenous haloperidol or chlorpromazine is more effective in improving agitation and communication in agitated delirium at the end of life. PATIENTS AND
methodsAll terminally ill patients with delirium treated in 39 specialized palliative care services were enrolled via the web. Delirium diagnosis and severity (Delirium Rating Scale-revised-98<DRS-R98>) were evaluated at the start of treatment (T0) and 72 h later (T1), and the psychotropic drugs used concomitantly at T1 were investigated. We evaluated whether there was an improvement in DRS-R98 agitation-related item scores and DRS-R98 communication-related item scores at T1 in patients with agitated cancer who received intravenous haloperidol or chlorpromazine from T0, and whether a significant difference existed between the two groups.
resultsOf 818 enrolled participants, 424 experienced agitation at T0, comprising 183 in the haloperidol group and 68 in the chlorpromazine group. The concomitant benzodiazepine rates were 52% and 54% in the haloperidol and chlorpromazine groups, respectively. In both groups, improvement in DRS-R98 agitation item scores was observed at T1, but there was no significant difference in improvement between the two groups. Worsening in DRS-R98 communication item scores was observed in both groups at T1, but there was no significant difference in worsening scores between the two groups.
conclusionIntravenous haloperidol and chlorpromazine are not statistically different for terminal agitation. These results should be validated in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.